Biogen–Eisai’s lecanemab can slow disease progression a little, but at significant cost and risk of side effects
Tantalising press-released data on Biogen and Eisai’s lecanemab prompt questions without firm answers
Biogen’s aducanumab is stumbling into obscurity. Where does that leave the amyloid hypothesis?
© Royal Society of Chemistry Registered charity number: 207890
Site powered by Webvision Cloud